Clinical trial NCT01792843: Cognitive Phenotypes in Parkinson's Disease
Official title: Cognitive Phenotypes in Parkinson's Disease: Anatomical and Functional Correlates
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Parkinson Disease
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2013-02-15
Enrollment: 158
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Parkinson's disease, according to international criteria, irrespective of their disease stage or their current antiparkinsonian medication

Brief summary: * a data driven approach has identified different cognitive phenotypes in Parkinson's disease (PD)
* this heterogeneity possibly reflects the diversity of the neuronal damage caused by the disease
* we hypothesize that the different clinical presentations are associated to specific anatomical and functional correlates

Detailed description: Cognitive impairments are frequent in PD, even in non-demented patients. However, there is a substantial heterogeneity in the clinical presentation of cognitive deficits in PD 2 and also in their progression. This heterogeneity possibly reflects the diversity of the neuronal damage caused by the disease and recent studies suggest that these different clinical influence the risk of developing dementia.

Most studies on cognitive phenotypes in PD have used predefined categories, such as demented vs. non-demented, or PD-mild cognitive impairment vs. cognitively intact patients. However, such an approach may miss less obvious or unexpected presentations. To this end, in a first part of this study, we have used a data-driven approach (cluster analysis) to identify different cognitive phenotypes in PD. With such an approach where phenotypical profiles arise from the data without a priori assumptions, five cognitive presentations were identified: i°) cognitively intact patients (19.39%), ii°) patients with slight mental slowing and mild executive dysfunction (41.29%), iii°) patients with slightly impaired overall cognitive efficiency and deficits in all cognitive domains except recognition memory (12.93%), iv°) patients with severe mental slowing, impaired overall cognitive efficiency, and severe cognitive impairment in all domains, including memory (23.88%), and v°) patients with very severe impairment in all cognitive domains (2.51%). From these results, it could be hypothesized that cognitive deterioration in PD progresses along a continuum, with the exception of the fourth group that also exhibits memory deficits. This group may be characterized by a different underlying pathology, or comorbidity with Alzheimer's disease. The role of vascular factors has also to be considered.

The objectives of the current project are:

1. to validate the identified cognitive profiles prospectively in a new population using confirmatory cluster analysis.
2. to identify specific anatomical correlates for the identified cognitive profiles by magnetic resonance-imaging (MRI) scanning
3. to identify specific functional correlates of the identified cognitive profiles by high-density EEG (hd-EEG)

Eligibility criteria: Inclusion Criteria:

* Males or females;
* 18 to 80 years;
* Parkinson's disease, according to international criteria;
* Without neurological co-morbidity;
* Benefiting from health insurance;
* Having read and understood the information form and having signed the consent form.

Exclusion Criteria:

* Pregnant or breastfeeding women;
* Parkinsonian syndrome other than PD;
* Currently participating in an other clinical trial or study;
* Patient whose physical or mental condition is incompatible with the study assessments;
* Person under tutorship or curatorship;
* Subjects with claustrophobia
* Subjects carrying incompatible metallic devices such as pacemakers and certain mechanical valves
* PD patients treated by deep brain stimulation

Primary outcomes:
measure: Frequency (%) of the cognitive profile
timeFrame: 2 years
Secondary outcomes:
measure: Grey matter density (voxels)
timeFrame: 2 years
Other outcomes:
measure: EEG power (microvolts2)
timeFrame: 2 years
Locations:
city: Maastricht
country: Netherlands
facility: Maastricht University Medical Centre
Study officials:
affiliation: University Hospital, Lille
name: Kathy Dujardin, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Carey G, Lopes R, Viard R, Betrouni N, Kuchcinski G, Devignes Q, Defebvre L, Leentjens AFG, Dujardin K. Anxiety in Parkinson's disease is associated with changes in the brain fear circuit. Parkinsonism Relat Disord. 2020 Nov;80:89-97. doi: 10.1016/j.parkreldis.2020.09.020. Epub 2020 Sep 19.